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We describe a label-free integrative pharmacology on-target (iPOT) method to assess the pharmacology of
drugs at the b2-adrenergic receptor. This method combines dynamic mass redistribution (DMR) assays
usinganarrayofprobemolecule-hijackedcellswithsimilarityanalysis.ThewholecellDMRassaystrackcell
system-based, ligand-directed, and kinetics-dependent biased activities of the drugs, and translates their
on-targetpharmacologyintonumericaldescriptorswhicharesubjecttosimilarityanalysis.Wedemonstrate
that the approach establishes an effective link between the label-free pharmacology and in vivo therapeutic
indications of drugs.
E
mbraced by the ‘‘one gene, one drug, one disease’’ philosophy, drug development campaigns heavily invest
on high throughput screening (HTS)-compatible molecular characterization assays to search maximally
selective drugs (‘‘magic bullets’’) for target-based therapies
1. However, the best in class drugs are identified
more byserendipity thanby rational design
2, and prioritization of lead candidates is as muchan art as aprocess
3.
This is mostly due to the poor correlation between in vitro results and in vivo indication(s). To prioritize lead
candidates and predict their therapeutic potentials, biological fingerprints based on binding profiles
4, gene
expression profiles
5,6, cellular phenotypic effects
7, side-effects
8, and chemical structures
9,10 can be produced so
that these molecules can be directly compared and sorted. These fingerprint-based approaches are promising to
relate molecular, cellular and in vivo features of drug molecules to targets and diseases. However, these
approaches generally have poor resolution in the on-target pharmacology of a drug, the functional consequences
of the drug binding to a specific target. The binding profile of a drug does not directly translate to its functional
activity. The cellular phenotypic responses can differentiate antagonists from agonists, but suffer significantly in
targetspecificity,inpartduetothepresenceofcompensatorypathwaysandnetworkinteractions,andinpartdue
to the accuracy of the reference signature associated with a specific target or a cellular process
5. Furthermore,
diverse molecular assays have revealed pluridimensional efficacy (i.e., an assay readout dependent efficacy) of a
single drug acting through a specific target
11,12. Since these assays measure single end points downstream the
target activation, it is obviously challenging to directly compare and prioritize molecules based on multiple
individual assay results, thus making it difficult to comprehend the therapeutic potential of these molecules.
Theseproblemsmaybeovercomeifitwerepossibletoeffectivelyclusterdrugsbasedontheirinvitromultifaceted
on-target pharmacology.
G protein-coupled receptors (GPCRs) represent the largest and most successful class of druggable targets in
human genome. This is illustrated by b-adrenergic receptors (b-ARs). The b-ARs belong to class A GPCRs and
consists of b1-, b2- and b3-AR subtypes. Drug development against b-ARs has been fruitful in the past several
decades (Supplementary Table S1). b-blockers have been used for the treatment and management of cardio-
vascular conditions
13, migraine
14, and ophthalmic disorders
15, presumably due to blockage of the activation of
b1-receptor
16.b2-agonistshavebeenlongusedinandstillarethemosteffectivebronchodilatorsforthetreatment
ofasthma
17.Severalb-agonistsarealsousedforthetreatmentofcardiacdecompensation,anaphylaxis,sepsis,and
prematurelabor
18.However,neitherallbeta-blockersbehaveequallyfortreatingvariousheartdiseases,norareall
b2-agonists effective in the management of asthma. Togetherwith diversein vivoindications, thedistinct clinical
profiles of b-drugs have challenged our view of how drugs should be classified, which, in turn, should guide us
how to screen and test drugs in vitro
19.
Here we present a strategy to determine on-target pharmacology of drugs acting on GPCRs using label-free
integrative pharmacology on-target(iPOT). Central to iPOTis label-freewhole celldynamic mass redistribution
(DMR) assay
20–23. DMR assays use a label-free optical biosensor, as shown in Fig.1a, to non-invasively record a
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,150 nmofthesensorsurface
20.TheDMRisaverydiscerningassay
that gives highly texture data at the whole cell level
19,22. A drug-
induced DMR is often sensitive to cellular context, which can be
controlled using genetic manipulations or interventions with small
probe molecules. DMR measurements in these perturbed cells can
manifestthesensitivityofadrug-inducedDMRtothetarget(s)/path-
way(s) with which the small probe molecules intervene. Combining
DMR assays in a wide array of probe molecule perturbed cells with
similarity analysis can separate drugs based on their distinct on-
target pharmacology. We demonstrate that this strategy provides
an effective link between in vitro profiles and in vivo indications of
b-drugs.
Results
The principle of iPOT. The iPOT begins with the use of diverse
probe molecules to hijack a cell or cell system, followed by
profiling drugs with DMR assays. The DMR profiles obtained for
eachdrugarethentranslatedtoamulti-dimensionalcoordinatesuch
that all drugs tested can be compared using similarity analysis. The
probes are chosen to recapitulate signaling pathways downstream
the target as well as pharmacological activities of drugs, such that
the pathway biased activity, if any, of drugs can be systematically
surveyed. The probes can be toxins for G proteins, inhibitors for
kinases and activators for enzymes within the receptor signaling
cascades, or b-drugs themselves (Fig.1a). The DMR arising from
b-drugs in the probe pretreated cells are used directly for similarity
analysis, except that when the probes are b-drugs, the DMR arising
from epinephrine or propranolol are used as readouts (Fig.1b;
Table 1). The cell or system is chosen based on the known
signaling capacity of the target, although the cells that are derived
from in vivo action sites of the drugs can be used. Hijacking of the
cell with the probes redirects the signaling routes of the target,
thus manifesting the biased activity of drugs towards the probe-
intervened pathways. After translating the kinetic DMR profiles
into multidimensional coordinates, similarity is analyzed to
categorize drugs into distinct clusters. We assume that drugs
within a given (sub)cluster share a common mode of action
possibly linked to an in vivo indication. The iPOT effectively
integrates the system-based, ligand-directed, and kinetics-
dependent biased activities of the drugs.
iPOT profiles established a link between in vitro results and in
vivo indications of b-drugs. We implemented the iPOT to
characterize all b-drugs approved by the Food and Drug
Administration (FDA) (Supplementary Table S2). All b2-drugs
were profiled at 10 mM to achieve maximal signaling capacity and
to be amenable for HTS (Supplementary Table S3). Human
epidermoid carcinoma A431 was chosen to be the cell system since
its endogenous b2AR has been served as a model to elucidate the
b2AR signaling in the past
24. Before measuring the DMR induced by
b-drugs, A431 was preconditioned under eight different conditions:
(1)theassayvehiclefor1hrasacontrol;(2)1mMpropranolol(PRO)
for 1 hr; (3) 5 nM epinephrine (EPI) for 1 hr; (4) 5 nM EPI for 5 hrs;
(5) 400 ng/ml Chorea toxin (CTx) for overnight; (6) 100 ng/ml
Pertussis toxin (PTx) for overnight; (7) 10 mM 4,5,6,7-tetrabromo-
benzotriazole (TBB) for 1 hr; and (8) 10 mM U0126 for 1 hr. We also
measured the EPI DMR in cells after pretreated with 10 mM b-drugs
for 1 hr or 5 hrs, the b-drug DMR in the presence of 10 mM forskolin
(FSK), and finallythe PRO DMR incells afterpretreated with 10mM
b-drugs for 5 hrs (Fig.1b). Total twelve DMR profiles were collected
for each drug (Table 1).
Figure 1 | The principle of the iPOT. The iPOT combines DMR assays with similarity analysis to assess on-target pharmacology of the b-AR drugs.
(a) Resonant waveguide grating biosensor for receptor signaling. The biosensor uses leaky mode nano-grating waveguide structure to generate an
evanescent wave to sensor whole cell responses. Cells are directly cultured onto and become adherent to the biosensor surface via adhesion complexes.A
schematic of b2-AR signaling pathway is also included. The intervention with various probe molecules of distinct signaling proteins in the b2-AR
pathway can be used as the basis to determine the on-target pharmacology of various b-drugs. (b) Assay protocols that use various probe molecules to
precondition a cell expressing the b2-AR for reporting DMR pharmacology of the b-drugs. (c) A numerical descriptor of a b-drug-induced DMR. The
responses at four distinct time points were extracted and color coded. Red: positive value; green: negative value; black: close to zero. The DMR was
obtained by stimulating native A431 with salmeterol at 10 mM.
www.nature.com/scientificreports
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points. To improve the efficiency of similarity analysis, we reduced
theDMRdimensionstofourdistincttimepoints(3,5,9,and45 min
post stimulation) (Fig.1c). The dimension reduction is based on
clustering of time domains of the DMR of all b-drugs in the
DMSO treated cells (Supplementary Fig.S1). Results showed that
theb-drugDMRgenerallypropagatewithfourdistincttimeperiods:
immediate (2–4 min), early (5–6 min, and 7–9 min), and late res-
ponses (10–60min post stimulation). Similar pattern was obtained
for all DMR signals under all twelve conditions. Thus, we selected
one time point from each period to represent each DMR, and we
found that these time points adequately represent the key features of
the drug responses (Supplementary Fig.S2 and S3). Thus, the twelve
DMR profiles of each drug can be rewritten into a 48 dimensional
coordinate.
Similarity analysis using unsupervised Ward hierarchical cluster-
ing algorithm and Euclidean distance metrics
25 categorized drugs
into distinct clusters (Fig.2). Detailed analysis revealed several inter-
estingaspects.First,theDMRassaysarehighqualityingeneral,since
twoisomersandtheir mixtureof propranolol ledtosubtledifference
in DMR profiles but were still bucketed together; and the same was
trueforS-isomeranditsmixtureofpindolol.Further,theb2-inactive
R-(1)-atenolol was clearly different from its active isomer, S(-)-ate-
nolol. R-(1)-atenolol was clustered with practolol and the negative
control dimethyl sulfoxide (DMSO). Practolol is a b1-selective but
much less potent b2-antagonist. Second, two superclusters were
formed; one for partial agonists and antagonists, and another for
strongpartialagonists,fullagonistsandtheadenylylcyclaseactivator
forskolin (FSK). Each supercluster is further divided into many sub-
clusters.Third,drugsineachsubclustersharealmostidenticalthera-
peutic indications as approved by the FDA and documented in
DrugBank
26, and the correlation between DMR profiles and in vivo
indications was correctly established for more than 90% of the drugs
tested. Notable disassociations between the DMR profiles and ori-
ginalindicationswere:(1)carvedilolwasclusteredwithPRO.Asmall
but positive clinical trial using carvedilol for the prophylactic treat-
ment of migraine has been reported in literature
27. (2) Terbutaline
was close to ritodrine, and to less degree, phenylephrine. Although it
is controversial and has not been approved by the FDA for tocolytic
use, terbutaline is the most widely prescribed beta-mimetic to arrest
or prevent premature labor inthe United States
18. (3)Salmeterol was
distinct from all other anti-asthma agonists. (4) Timolol was distinct
fromPROalthoughtimololisalsousedfortreatingmigraine.(5)The
active metabolite (methylnorepinephrine) of methyldopa was close
to norepinephrine.
WefurthercomparedtheresultsobtainedwithDMRprofileswith
those obtained using in vivo indications or chemical features.
Clusteringofb-drugsbasedontheirinvivoindications,asdocumen-
ted in DrugBank, led to a relatively low resolution heat map (Fig.3a).
For this analysis, a binary numeral system, 1 for an approved indica-
tion and 0 for none, is used to describe each drug based on their
clinical indications. We also analyzed the chemical similarity of all
b-drugstestedusingChemMine
28.ChemMineisanonlineservicefor
analyzing and clustering small molecules. Chemical similarity based
on Tanimoto coefficient led to bucketing of compounds that shows
relatively poor correlation with their in vivo indications (Fig.3b).
These comparative analyses suggest that the iPOT gave rise to better
correlation between in vitro results and in vivo indications.
Correlation analysis identified the origin of similarity among
b-drugs. We used correlation analysis between distinct conditions
to further determine the origin of similarity/difference among
b-drugs. We used seven assays to separate b-drugs based on
agonism, specificity, potency, and kinetics-dependent mechanisms
of activation and inactivation. First, we recorded the DMR arising
fromalldrugsinthenativecells.Resultsshowedthattherewerethree
classes of drugs: full agonists that triggered a DMR similar to the EPI
DMR; partial agonists that led to a DMR smaller than the EPI DMR;
and apparent inactive drugs that led to a net-zero DMR
(Supplementary Fig.S3). Second, we examined the impacts of b-
drugs on the succeeding EPI DMR, wherein the cells were
pretreated with b-drugs for 1hr or 5hr. Results suggest that S-(-)-
atenolol, (6)atenolol and practolol exhibited weak antagonism,
while dobutamine and dopamine led to weak agonism, but R-(1)-
atenolol was inactive (Fig.4a). However, the EPI DMR after the cells
were pretreated with b-drugs for 5hr showed that dobutamine and
dopamine caused a complete desensitization, but bisprolol and
acebutolol led to a reduced blockage of the succeeding EPI DMR
(Fig.4a; supplementary Fig.S4). Third, we examined the DMR
induced by b-drugs after the cells were pre-activated with 5 nM
EPI for 1 hr or 5hr. Results showed that there was a linear
correlation between the two DMR for most b-drugs (Fig.4b). The
drugs in the cells after the longer EPI pretreatment generally led to a
more positive DMR. However, the DMR arising from satolol,
R(1)atenolol, carvedilol, and (6)-, R-(1)- and S-(-)-propranolol
were largely insensitive to the pretreatment duration with EPI
(Fig.4b; Supplementary Fig.S5 and S6). Fourth, we examined the
ability of PRO to block the DMR arising from b-drugs, wherein
PRO was used to pre-stabilize the receptor at its inactive
conformation. This further separated b-drugs based on potency
(Fig.5a). The percentage of inhibition by PRO was mostly inversely
correlatedwiththepotency(i.e.,KiorEC50, cAMP)ofanagonistdrug,
except for a group of partial agonist drugs that include pindolol,
alprenolol, oxprenolol, labetalol and isoetharine (Supplementary
Table 1 | Assay protocols and DMR signals used for similarity and correlation analysis.
Assay number Probe, pretreatment duration DMR readout Note
1 0.1% DMSO, 1hr Ligand, 10 mM Positive control, agonism
21 0 mM Ligand, 1hr Epinephrine, 5 nM Specificity, relative potency and efficacy, modes of action
31 mM propranolol, 1hr Ligand, 10 mM Specificity, relative potency and efficacy, modes of action
4 5 nM Epinephrine, 1hr Ligand, 10 mM Receptor desensitization and deactivation
51 0 mM ligand, 5hr Epinephrine, 5nM Kinetics dependent receptor blockage by antagonists and
receptor desensitization by agonists
6 5 nM Epinephrine, 5hr Ligand, 10 mM Kinetics dependent deactivation of the receptor after
prolonged activation with epinephrine
71 0 mM ligand, 5hr Propranolol, 10 mM Relative potency, kinetics dependent agonism
8 0.1% DMSO, 1hr Forskolin 10 mM cAMP-PKA pathway
Ligand, 10 mM
9 400 ng/ ml cholera toxin, 20hr Ligand, 10 mMG as-dependent and independent activity
10 100 ng/ml pertussis toxin, 20hr Ligand, 10 mMG ai sensitivity
11 10 mM TBB, 1hr Ligand, 10 mM CK2 sensitivity
12 10 mM U0126, 1hr Ligand, 10 mM MEK1/2 sensitivity
www.nature.com/scientificreports
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adrug-induced DMRafter thedrugwasexposedtothecells for5hrs
(Fig.5b). This further separated agonist drugs, in which PRO
reversed the DMR arising from distinct agonist drugs to different
degrees (Supplementary Fig.S8).
Next, we used three assays to delineate drug pharmacology based
on G protein-dependent and independent signaling. First, we exam-
ined the DMR induced by FSK in the absence and presence of a
b-drug (Fig.6a), wherein FSK was used to activate adenylyl cyclases.
This delineated drugs into three groups: drugs that suppressed the
FSK DMR, drugs that potentiated the FSK DMR with an accelerated
kinetics, and drugs that had little impact on the FSK DMR
(Supplementary Fig.S9). Notable is salmeterol which significantly
potentiated the FSK DMR, unlike all other strong partial and full
agonists. Second, we compared the b-drug DMR without and with
the pre-decoupling of Gas proteins from the receptor by CTx
(Fig.6b). This identified drugs that still produced noticeable DMR
(e.g.,EPI,alprenolol),orledtoanincreasedDMR(e.g.,carvedilol)in
the CTx-pretreated cells (Supplementary Fig.S10). Third, we com-
paredtheb-drugDMRwithoutandwiththemaskingofGaiproteins
byPTx (Fig.7a). This resulted in alinear correlation between the two
DMR,but withaslope of 0.95,suggesting that theimpairmentofGai
by PTx suppressed all b-drug-induced DMR.
Finally,weusedthreeassaystoprobeligand-directedbiasedagon-
ism. First, we used a MEK1/2 inhibitor U0126 to inhibit the activity
of MEK1/2. This led to a linear correlation with a slope significantly
greater than 1 between the two DMR arising from b-drugs without
and with the U0126 pretreatment (Fig.7a). This also identified prac-
tolol and oxprenolol, both of which led to a suppressed DMR by
U0126 (Supplementary Fig.S11). Second, we examined the impacts
of a Casein kinase (CK2) inhibitor TBB on the drug-induced DMR
(Fig.7b), wherein TBB was used to precondition the cells with sup-
pressed CK2 activity. Distinct drugs exhibited different sensitivities
to the TBB treatment (Supplementary Fig.S12). Third, we compared
a drug-induced DMR with its whole cell cAMP signal (Fig.8). This
identified DMR-biased drugs including practolol, alprenolol, pindo-
lol, labetalol, acebutolol, and dopamine. Dopamine was previously
showntobemoderatelypotenttotriggerDMRsignalinA431cells
29.
Discussion
In contrast to conventional molecular assays that are biased towards
a single pathway and/or a single molecule, the integrative readout of
DMR assays allows assessing drug pharmacology with wide pathway
coverage. The imminent high temporal resolution makes DMR
assays possible to quantify drug pharmacology at different time
domains. The non-invasive measure enables DMR assays to probe
Figure 2 | DMR heat map of clinically available b-drugs. This heat map was obtained using DMR profiling of the drugs under twelve conditions,
followedbysimilarityanalysisusingtheWardhierarchicalclusteringalgorithmandEuclideandistancemetrics.ThetwelveDMRusedforanalysiswere:a
drug-induced DMR in the cells pretreated with the assay vehicle for 1 hr (Buffer – AR), 1 mM propranolol for 1 hr (PRO – AR), 5 nM EPI for 1 hr
(EPI – AR), 5 nM EPI for 5 hrs (EPI5h – AR), 400 ng/ml CTx for overnight (CTx – AR), 100 ng/ml PTx for overnight (PTx – AR), 10 mM TBB for 1 hr
(TBB – AR), and 10 mM U0126 for 1 hr (U-126 – AR). In addition, we also included an EPI-induced DMR in the cells pretreated with 10 mM b-drugs for
1 hr (AR – EPI) and for 5 hrs (AR5h – EPI); an PRO-induced DMR in the cells pretreated with 10 mM b-drugs for 5 hrs (AR5h – PRO); and a forskolin
(FSK)-induced DMR in the presence of b-drugs (FSK 1 AR).
www.nature.com/scientificreports
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used as a basis for similarity analysis.
www.nature.com/scientificreports
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assays are robust and reproducible (Supplementary Fig.S13).
Combining DMR assays with similarity analysis can differentiate
drug pharmacology with relatively high resolutions. We implanted
theiPOTtoinvestigatethepharmacologyofclinicallyavailableb-AR
drugs. Using twelve DMR assays in a cell line endogenously expres-
sing theb2-ARunder distinct chemical environments, wefound that
clinically approved b-AR drugs are divergent in their potency,
mechanisms of activation and inactivation, and pathway biased
activity. Although only a first step, our results are encouraging.
The most notable finding is that the iPOT profiling of b-AR drugs
established an apparently effective link between in vitro results and
in vivo indications. iPOT profiles of drugs in disease relevant cells,
togetherwithglobalanalysisofdrugsagainstthefamilyofadrenergic
receptors, would further strengthen the correlation between in vitro
and in vivo results.
SinceDMRisanintegratedmeasure ofreceptorsignaling, specific
biological events that underlie the similarity and differences among
distinct drugs are still largely unknown
30. The linkage between a
specific DMR parameter and a specific clinical feature is also largely
unknownatthepresenttime.Furtherdelineationofreceptorbiology
anddrug pharmacology,togetherwithoptimization of algorithmfor
similarity analysis, would be necessary to validate the link between
the iPOT testing results and in vivo indications, and to make it
possible to rank and select drugs within a class for in vivo testing
during lead selection process. Nonetheless, the high content assess-
ment of drug pharmacology with label-free iPOT assays elucidates
thecomplexandmultifacetedefficacyofGPCRligands,thusoffering
a practical process to reposition drugs for new indications
31,32and to
prioritize lead molecules.
Methods
Cell lines and reagents. Human epidermoid carcinoma A431 was obtained from
American Type Cell Culture. The cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 4.5g/liter
glucose, 2 mM glutamine, and antibiotics. The native cells were passed when
approaching,90%confluencewithtrypin/EDTA(etthylenediaminetetraaceticacid)
toprovidenewmaintenanceculturesonT-75flasksandexperimentalculturesonthe
biosensor microplates. All drug molecules were purchased from commercial sources
(Supplementary Table S2). All drugs were dissolved in DMSO and were diluted
directly into the assay buffer (13 Hanks’ balanced salt buffer, 20mM Hepes, pH 7.1;
HBSS) to the indicated concentrations. EpicH 384-well tissue culture treated
biosensor microplates were obtained from Corning Incorporated (Corning, NY,
USA).
DMRassays.EpicHsystem(CorningInc.),awavelengthinterrogationreadersystem
tailored for resonant waveguide grating (RWG) biosensors in microtiter plates, was
used for all DMR assays. This system consists of a temperature-control unit (26uC),
an optical detection unit, and an on-board liquid handling unit with robotics. The
detection unit is centered on integrated fiber optics, and enables kinetic measures of
cellular responses with a time interval of ,15sec. 20,000 cells per well were directly
seeded and cultured overnight under serum rich medium, followed by starvation
overnight using serum depleted medium. After washed twice, the cells were
maintained with HBSS and further incubated inside the system for 1hr. A 2-min
baseline was then established. Immediate after the compound additions using the
onboardliquidhandler,thecellularresponses wererecorded.Allstudieswerecarried
out with at least three replicates.
Figure 5 | Correlation analysis identifies the origin of similarity among
distinct b-drugs based on potency, mechanisms of activation and
deactivation. (a) Scatter plots between the b-drug-induced DMR without
and with the pretreatment with PRO for 1hr; (b) scatter plots between the
b-drug-induced DMR in native cells and the PRO-induced DMR in the
cells after 5hr pretreatment with b-drugs.
Figure 4 | Correlation analysis identifies the origin of similarity among
distinct b-drugs based on potency, mechanisms of activation and
deactivation. (a)Scatterplotsbetweentheb-drug-inducedDMRinnative
cells and the EPI-induced DMR after pretreated with drugs for 1hr (black
dots)or 5hr(pinkdots); and(b)scatter plots betweenthe b-drug-induced
DMR in cells after pretreatment with EPI for 1hr and 5hr.
www.nature.com/scientificreports
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against 12 distinct assay conditions using kinetic DMR assays. Drug concentrations
were chosen to achieve maximum efficacy and to be amenable for high throughput
screening (Supplementary Table S3). A431 cells were preconditioned with probe
moleculestoachieveawiderangeofchemicalenvironments,which,inturn,manifest
the specificity, relative potency and efficacy, and modes of action of the drugs. The
chemical environments also enable mapping the cell systems-based, ligand-directed
and kinetics-dependent biased agonism of the drugs. Specifically, cells were
pretreated with DMSO (the positive control), 5nM epinephrine, 1mM propranolol,
400ng/ml cholera toxin, 100ng/ml pertussis toxin, U0126, 4,5,6,7-
tetrabromobenzotriazole, forskolin, and the drug molecules for a specific period of
time (Table 1). Afterwards, cells were stimulated with a b2-ligand (epinephrine,
propranolol, or the drug), whose responses were recorded in real time and used for
similarity and correlation analysis.
Whole cAMP assays. Cells were plated in 384well tissue culture treated plates (BD
Bioscience, Cat# 354660) with a seeding density of 20000 cells per well. Cells were
cultured in the serum rich medium overnight. The next day cAMP-Glo assay was
performed according to manufacturer’s instruction (Promega, Cat#V1502). Cells
were incubated with 10 mM compounds in induction buffer for 30 minutes before
adding lysis buffer. Luminescence was measured using Tecan SafireII reader.
Data visualization and clustering. For each DMR the responses at the four distinct
time points (Fig.1c) were extracted for reduction of the time dimensions. All time
points refer to the stimulation duration after renormalized the responses starting
from t0 (the time when the compound was added) (Fig.1c). For visualization purpose
the responses were color coded to illustrate relative differences in DMR signal
strength.Thetotal48dimensions, 4foreachcondition,werethusobtainedtorewrite
theDMRpharmacologyofadrug.Inthedrugmatrix(Fig.2)eachcolumn represents
one DMR response at a particular time in a specific assay condition, and each row
represents one drug with the original approved indications, as documented in
DrugBank (Http://www.drugbank.ca). Every row and column carries equal weight.
The Ward hierarchical clustering algorithm and euclidean distance metrics (http://
www.eisenlab.org/eisen/) were used for clustering the results. DMSO in the vehicle, a
concentration that equals to those for all drugs, is also included as a negative control.
For replicates, we used statistical differences using the four chosen time points to
calculatethevariabilityamongreplicates.Allreplicateshavetopassthe23coefficient
of variation test before being included in analysis. The drugs whose DMR responses
failed the test are re-screened. For clinical indications, each drug was written using a
binary numeral system, 1 for a clinical indication as documented in DrugBank and 0
for none. For chemical structures, all drugs were analyzed using ChemMine online
software, which employs atom pairs as structural descriptors and Tanimoto
coefficient as a similarity measure. Hierarchical clustering was used for clustering
based on both clinical features and chemical structures.
Figure 7 | Correlation analysis identifies the origin of similarity among
distinct b-drugs based on pathway biased agonism. Scatter plots between
the b-drug-induced DMR innativecells and inthe cells after pretreatment
with PTx (black dots) or U0126 (pink dots) (a), and TBB (b).
Figure 8 | Correlation between the b-drug-induced DMR in native cells
and the whole cell cAMP level induced by b-drugs.
Figure 6 | Correlation analysis identifies the origin of similarity among
distinct b-drugs based on pathway biased agonism. (a) Scatter plot
between the b-drug-induced DMR in native cells and the FSK DMR in the
presence of distinct b-drugs; (b) Scatter plot between the b-drug-induced
DMR in native cells and in the cells after pretreatment with CTx.
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